AP Biosciences Inc
6945
Rank in Stocks
#14177
AP Biosciences Inc. is a pioneering clinical-stage biopharmaceutical company... AP Biosciences Inc. is a pioneering clinical-stage biopharmaceutical company dedicated to the research and development of bispecific antibody drugs, aiming to fulfill critical unmet medical needs. Its robust pipeline features several promising candidates: Leading the pack, IBI302 is in Phase III clinical trials for the treatment of neovascular age-related macular degeneration (nAMD). Further along, AP505 is undergoing Phase I clinical trials for various solid tumors. AP203, also in Phase I, is being investigated for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous cell carcinomas. In earlier development, AP402 is currently in the pre-clinical research phase, focusing on breast cancer patients. Additionally, AP601 is also in pre-clinical research, targeting a broader spectrum of malignancies including lung cancer, pancreatic cancer, bladder cancer, ovarian cancer, and other solid tumors. Founded in 2013, the company maintains its headquarters in Taipei City, Taiwan.
Share Price
$3.49
Last synced: 2026-11-10
Market Cap
$340.43M
Change (1 day)
2.23%
Change (1 year)
-5.10%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade AP Biosciences Inc (6945)
Category
Healthcare
EPS for AP Biosciences Inc (6945)
EPS as of June 2026 TTM: $-0.17
According to AP Biosciences Inc's latest financial reports, its current EPS (TTM) is $-0.17. At the end of 2025 the company had an EPS of $-0.17, equal to its 2024 EPS of $-0.17.
EPS history for AP Biosciences Inc from 2020 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.17 | -1.94% |
| 2025 | $-0.17 | -2.52% |
| 2024 | $-0.17 | 0.06% |
| 2023 | $-0.17 | -4.42% |
| 2022 | $-0.18 | 27.37% |
| 2021 | $-0.14 | 0.00% |
| 2020 | 0.00 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -9,494.12% |
US
|
|
| $-7.07 | 4,141.15% |
US
|
|
| $-5.29 | 3,073.37% |
AU
|
|
| $12.88 | -7,826.51% |
BE
|
|
| $21.56 | -13,033.41% |
NL
|
Questions about AP Biosciences Inc's earnings per share (EPS)
What is AP Biosciences Inc's earnings per share (EPS)?
AP Biosciences Inc's earnings per share (EPS) over the last twelve months is $-0.17, as of Jun 2026.
What was AP Biosciences Inc's earnings per share (EPS) in 2025?
In 2025, AP Biosciences Inc's earnings per share (EPS) was $-0.17, compared with $-0.17 in 2024.
How has AP Biosciences Inc's earnings per share (EPS) changed since 2020?
From 2020 to 2025, AP Biosciences Inc's earnings per share (EPS) was highest in 2020 (0.00) and lowest in 2022 ($-0.18).
How does AP Biosciences Inc's earnings per share (EPS) compare with similar companies?
AP Biosciences Inc's earnings per share (EPS) ($-0.17) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.